重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合抗风湿药物治疗中重度银屑病的临床观察被引量：7

The observation of rhTNFR:Fc combined with anti rheumatic drugs in the treatment of moderate to severe plaque psoriasis

暂未订购

导出

摘要目的:观察重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白(rhTNFR:Fc商品名:益赛普)联合抗风湿药物(甲氨蝶呤、来氟米特)治疗中重度银屑病的疗效及安全性。方法:选取本院就诊的78例中重度银屑病患者,其中45例应用rhTNFR:Fc联合甲氨蝶呤、来氟米特治疗为观察组,33例采用单纯抗风湿药物(甲氨喋呤联合来氟米特)治疗为对照组。观察并比较用药前及用药后2周、4周、8周、12周、24周两组的PASI指数及不良反应。结果:治疗8周后两组的PASI50差异有统计学意义(P<0.05),治疗12周及24周后两组PASI50、PASI75、PASI90的比例高于对照组,差异均有统计学意义(P<0.05),两组之间不良反应发生率比较差异无统计学意义(P>0.05)。结论:rhTNFR:Fc联合甲氨蝶呤、来氟米特治疗中重度银屑病疗效显著,值得临床推广。 Objective: To observe the clinical effiency and safety of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:Ig G Fc Fusion Protein(rhTNFR),combined with anti rheumatic drugs(methotrexate,leflunomide) in treatment of moderate to severe plaque psoriasis.Methods: 78 patients of moderate to severe plaque psoriasis treated in our department were selected,45 cases of the observation group treated with rhTNFR: Fc combined with methotrexate(MTX) and leflunomide(LEF),33 cases of the control group treated with MTX + LEF.The severity index scores(PASI) and adverse reaction before treatment and at 2,4,8,12 and 24 weeks after treatment were observed.Results: After 8 weeks of treatment,the difference of PASI50 between the two groups was statistically significant(P < 0.05).After 12 weeks and 24 weeks,the ratio of PASI50,PASI75 and PASI90 in the two groups was significantly higher than that in the control group,and the differences were statistically significant(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05).Conclusion: It's effective and safety of rhTNFR: Fc combined with MTX and LEF for the treatment of moderate to severe plaque psoriasis,which is worthy of clinical promotion.

作者张杰李江涛邓文郁肖岚陈芍

机构地区宜宾市第一人民医院风湿免疫科

出处《川北医学院学报》 CAS 2017年第6期852-854,共3页 Journal of North Sichuan Medical College

基金四川省卫计委科研项目(110599) 宜宾市科技局基金项目(2012SF004)

关键词重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白银屑病甲氨喋呤来氟米特 rhTNFR:Fc Psoriasis Methotrexate Leflunomide

分类号 R758.6 [医药卫生—皮肤病学与性病学]

引文网络
相关文献

参考文献2

1马晓蕾,周城,蔡林,李文海,张建中.生物制剂治疗银屑病的研究进展[J].临床皮肤科杂志,2012,41(9):577-579. 被引量：22
2无,郑志忠(执笔).中国银屑病治疗指南（2008版）[J].中华皮肤科杂志,2009,42(3):213-214. 被引量：195

二级参考文献20

1赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009,12:744.
2Gottliob AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis[J]. Clin Immumol, 2002, 105:105-116.
3Kimball AB, Gordon KB, Langley RG, et al. Safey and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal anti- body,in the treatment of moderate to severe chronic plaque pso- riasis:results of a randomized, placebo-controlled,phase 2 trial[J]. Arch Dermatol, 2008, 144(2): 200-207.
4Korman BD, Tyler KL, Korman N2. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cau- tionary tale for dermatologists[J]. Arch Dermatol, 2009, 145:(8) 937-942.
5Van de Kerkhnf P, Griffths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patiats for whom conventional therapies are inadrquete[J]. Dermatology, 2005, 211(3): 256-263.
6Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J]. Lancet, 2001, 357(9271): 1842-1847.
7Fortaleza GT, Brito Mde F, Santos JB. Splenic tuberculosis dur- ing psoriasis treatment with infliximab [J]. An Bras Dermatol, 2009, 84(4): 420-424.
8Turner D, Picot J, Cooper K, et al. Adalimumab for the treat- ment of psoriasis[J]. Health Technology Assessment, 2009, 13(2): 49-54.
9Schmitt J, Wozel G. Tageted treatment of psoriasis with adali- mumab: a critical appraisal based on a systematic review of the literature[review] [J]. Biologies: Targets and Therapy, 2009, 13(3): 303-318.
10Blomberg M, Zaehariae C, Gronhoj F. Hyperpigmentation of the face following Adalimumab Treatment [J]. Journal Compilation, Acta Dermato-Venerologica, 2009, 89(5): 546-547.